Get the Stockscreener App
50.57
0.98%
-0.50
Pre-market:
50.64
0.07
+0.14%
Qiagen Nv stock is traded at $50.57, with a volume of 1.02M.
It is down -0.98% in the last 24 hours and up +5.86% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$51.07
Open:
$50.72
24h Volume:
1.02M
Relative Volume:
0.74
Market Cap:
$11.06B
Revenue:
$1.98B
Net Income/Loss:
$83.59M
P/E Ratio:
135.21
EPS:
0.374
Net Cash Flow:
$502.31M
1W Performance:
+0.34%
1M Performance:
+5.86%
6M Performance:
+13.61%
1Y Performance:
+9.96%
1-Day Range:
$50.26
$50.93
1-Week Range:
$50.26
$51.88
52-Week Range:
$37.74
$51.88
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
50.57 | 11.06B | 1.98B | 83.59M | 502.31M | 0.374 |
|
TMO
Thermo Fisher Scientific Inc
|
477.28 | 182.01B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
203.99 | 148.12B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
572.09 | 46.09B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
118.05 | 34.04B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.54 | 33.07B | 15.50B | 1.33B | 2.16B | 7.34 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
How strong is Qiagen N.V. company’s balance sheetBeginner Investor Review Backed By Experts - jammulinksnews.com
What is the dividend policy of Qiagen N.V. stockLow Risk Forecasts For Smart Trading - jammulinksnews.com
Why Qiagen N.V. stock attracts strong analyst attentionShort Term Setup With Predictive Chart Confirmed - beatles.ru
Qiagen N.V. Announces BlackRock’s Significant Stake in Voting Rights - TipRanks
Will Qiagen N.V. Benefit From Sector TailwindsTop Performing Stock Insights Released Daily - metal.it
Key External Factors That Drive Qiagen N.V. Stock Price MovementsEntry Plan for Oversold Reversal Stocks Released - metal.it
Chart Analysts Warn of Resistance Near Qiagen N.V. PriceBuy Alerts With Low Risk Confirmation Noted - metal.it
Is Qiagen N.V. a Top Dividend Stock to Watch in 2025Scalable Portfolio Growth Suggestions Released - metal.it
COVID-19 Saliva-Based Detection Kits Market to reach US$ 1.2 Bn - openPR.com
Why is Qiagen N.V. stock attracting strong analyst attentionCapitalize on market trends before they peak - jammulinksnews.com
When is Qiagen N.V. stock expected to show significant growthUnlock superior stock analysis tools - jammulinksnews.com
What are the latest earnings results for Qiagen N.V.Take advantage of unprecedented market momentum - jammulinksnews.com
What makes Qiagen N.V. stock price move sharplyAccess powerful market insights for free - jammulinksnews.com
What are analysts’ price targets for Qiagen N.V. in the next 12 monthsStay ahead with daily expert stock picks - jammulinksnews.com
What are Qiagen N.V. company’s key revenue driversInvest confidently with professional market insights - jammulinksnews.com
Qiagen Sees Price Target Raised to EUR 50 by Berenberg Analyst - AInvest
What analysts say about Qiagen N.V. stockOutstanding trading profits - PrintWeekIndia
Qiagen Announces BlackRock’s Significant Voting Rights - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Is Qiagen N.V. a good long term investmentLightning-fast capital gains - PrintWeekIndia
What drives Qiagen N.V. stock priceFree Investment Portfolio Suggestions - PrintWeekIndia
Berenberg Bank Maintains Qiagen NV(QGEN.US) With Buy Rating, Raises Target Price to $58.72 - 富途牛牛
Qiagen (QGEN) Sees Price Target Raised by Berenberg Analyst | QGEN Stock News - GuruFocus
Qiagen N.V.'s (NYSE:QGEN) high institutional ownership speaks for itself as stock continues to impress, up 4.3% over last week - Yahoo Finance
Berenberg raises Qiagen stock price target to EUR50 on growth pillars - Investing.com Canada
Berenberg raises Qiagen stock price target to EUR50 on growth pillars By Investing.com - Investing.com South Africa
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term - Yahoo Finance
QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels - BioSpace
BlackRock Discloses Significant Stake in Qiagen - AInvest
QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - Pressetext
Qiagen Announces Voting Rights Notification Involving BlackRock - TipRanks
BlackRock’s Significant Stake in Qiagen Disclosed by AFM - TipRanks
QIAGEN launches long read sequencing panels for complex genomic analysis - StreetInsider
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen N.V. Stock Analysis and ForecastUnmatched profit growth - jammulinksnews.com
Qiagen NV stock reaches 52-week high at 48.91 USD By Investing.com - Investing.com Canada
Qiagen NV stock reaches 52-week high at 48.91 USD - Investing.com India
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):